ArticleFuture oncology (London, England)2011

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Alen Ostojic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.